失眠对ADHERE注册研究中舌下神经刺激疗效的影响
研究分析ADHERE注册研究2020年3月至2022年9月的观察性数据,评估舌下神经刺激(HGNS)治疗阻塞性睡眠呼吸暂停(OSA)患者中基线失眠的患病率及对疗效的影响。928例患者中62%基线失眠严重指数(ISI)≥15;ISI≥15与ISI<15两组在呼吸暂停低通气指数(AHI)下降和依从性上无差异,但ISI≥15组嗜睡改善更明显;所有患者随访时失眠评分均改善。
要点
- ADHERE注册研究中62%的HGNS治疗患者基线ISI≥15,即存在中度至重度失眠。
- 基线ISI≥15与ISI<15两组间AHI下降和每晚使用依从性无显著差异。
- 基线ISI≥15组在滴定后和最终访视时ESS改善程度大于ISI<15组(p=0.014,0.025)。
核心结论
- 随访时ISI严重程度亚组间HGNS治疗的疗效和依从性相似。
- 所有接受HGNS治疗的患者失眠和嗜睡评分均改善,基线中度/重度失眠者改善程度更大。
研究设计与样本
- 分析ADHERE注册研究2020年3月至2022年9月的观察性数据。
- 928例患者获得基线ISI;578例和141例分别达到12个月和24个月时间点完成滴定后和最终访视,其中292例(50.5%)和91例(64.5%)完成了ISI。
- 比较基线ISI<15与ISI≥15亚组在滴定后和最终访视时的AHI、ISI、ESS及每晚使用情况。
主要发现
- 基线ISI≥15者占62%;基线心理健康状况在ISI≥15组高于ISI<15组(p<0.001)。
- 基线ISI≥15与ISI<15两组间AHI下降和依从性无差异。
- 滴定后和最终访视时,基线ISI≥15组ESS改善大于ISI<15组(p=0.014,0.025)。
- 所有患者随访时夜间、日间和总体ISI评分均改善(p<0.001),基线ISI≥15组较ISI<15组改善更明显(p<0.05)。
局限性
- 证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine the preoperative prevalence of insomnia in the Adherence and Outcomes of Upper Airway Stimulation for OSA International Registry (ADHERE) and to examine serial sleep-related data longitudinally, in particular the Insomnia Severity Index (ISI), to compare outcomes between patients with no/subthreshold insomnia (ISI < 15) and moderate/severe insomnia (ISI ≥ 15) at baseline. METHODS: We analyzed observational data from ADHERE between March 2020 and September 2022. Baseline demographic and mental health (MH) data, apnea hypopnea index (AHI), ISI, and ESS (Epworth Sleepiness Scale) were recorded. At post-titration (PT) and final visits, AHI, ISI, ESS and nightly usage were compared between baseline ISI < 15 and ISI ≥ 15 subgroups. RESULTS: A baseline ISI was obtained in 928 patients (62% with ISI ≥ 15). Of the 578 and 141 patients reaching the 12- and 24-month time periods to complete PT and final visits, 292 (50.5%) and 91 (64.5%) completed the ISI, respectively. Baseline MH conditions were higher with ISI ≥ 15 than ISI < 15 (p < 0.001). AHI reduction and adherence did not differ between patients with baseline ISI ≥ 15 and ISI < 15. Patients with ISI ≥ 15 experienced greater improvement in ESS than ISI < 15 at post-titration and final visits (p = 0.014, 0.025). All patients had improved nocturnal, daytime, and overall ISI scores at follow-up visits (p < 0.001), especially for those with baseline ISI ≥ 15 compared with ISI < 15 (p < 0.05). CONCLUSION: HGNS therapy efficacy and adherence were similar between ISI severity subgroups at follow-up visits. Insomnia and sleepiness scores improved in all patients with HGNS therapy and to a greater degree in patients with baseline moderate/severe insomnia. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:471-479, 2024.
引用
- Dhanda Patil R, Ishman SL, Chang JL, et al. Impact of Insomnia on Hypoglossal Nerve Stimulation Outcomes in the ADHERE Registry. Laryngoscope. 2023. PMID: 37560883. doi:10.1002/lary.30933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。